Literature DB >> 33727138

NMS-873 functions as a dual inhibitor of mitochondrial oxidative phosphorylation.

Miranda F Bouwer1, Kathryn E Hamilton1, Patrick B Jonker1, Sam R Kuiper1, Larry L Louters1, Brendan D Looyenga2.   

Abstract

Small-molecule inhibitors of enzyme function are critical tools for the study of cell biological processes and for treatment of human disease. Identifying inhibitors with suitable specificity and selectivity for single enzymes, however, remains a challenge. In this study we describe our serendipitous discovery that NMS-873, a compound that was previously identified as a highly selective allosteric inhibitor of the ATPase valosin-containing protein (VCP/p97), rapidly induces aerobic fermentation in cultured human and mouse cells. Our further investigation uncovered an unexpected off-target effect of NMS-873 on mitochondrial oxidative phosphorylation, specifically as a dual inhibitor of Complex I and ATP synthase. This work points to the need for caution regarding the interpretation of cell survival data associated with NMS-873 treatment and indicates that cellular toxicity associated with its use may be caused by both VCP/p97-dependent and VCP/p97-independent mechanisms.
Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  ATP synthase; Aerobic fermentation; Complex I; Oxidative phosphorylation; Small-molecule inhibitor; VCP/p97

Mesh:

Substances:

Year:  2021        PMID: 33727138      PMCID: PMC8119374          DOI: 10.1016/j.biochi.2021.03.004

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.372


  26 in total

Review 1.  Screening for positive allosteric modulators of biological targets.

Authors:  Duncan R Groebe
Journal:  Drug Discov Today       Date:  2006-07       Impact factor: 7.851

2.  Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.

Authors:  Syn Kok Yeo; Rhiannon French; Filomena Spada; Richard Clarkson
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

3.  p97 Composition Changes Caused by Allosteric Inhibition Are Suppressed by an On-Target Mechanism that Increases the Enzyme's ATPase Activity.

Authors:  Nam-Gu Her; Julia I Toth; Chen-Ting Ma; Yang Wei; Khatereh Motamedchaboki; Eduard Sergienko; Matthew D Petroski
Journal:  Cell Chem Biol       Date:  2016-04-21       Impact factor: 8.116

Review 4.  Potential functional and pathological side effects related to off-target pharmacological activity.

Authors:  James J Lynch; Terry R Van Vleet; Scott W Mittelstadt; Eric A G Blomme
Journal:  J Pharmacol Toxicol Methods       Date:  2017-02-16       Impact factor: 1.950

5.  The proteasome inhibitor PS-341 in cancer therapy.

Authors:  B A Teicher; G Ara; R Herbst; V J Palombella; J Adams
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

6.  Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives.

Authors:  R C Scaduto; L W Grotyohann
Journal:  Biophys J       Date:  1999-01       Impact factor: 4.033

7.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

8.  Essential function of VCP/p97 in infection cycle of the nucleopolyhedrovirus AcMNPV in Spodoptera frugiperda Sf9 cells.

Authors:  Yulia V Lyupina; Pavel A Erokhov; Oksana I Kravchuk; Alexander D Finoshin; Svetlana B Abaturova; Olga V Orlova; Svetlana N Beljelarskaya; Margarita V Kostyuchenko; Victor S Mikhailov
Journal:  Virus Res       Date:  2018-06-08       Impact factor: 3.303

9.  Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Authors:  Holger Siebeneicher; Arwed Cleve; Hartmut Rehwinkel; Roland Neuhaus; Iring Heisler; Thomas Müller; Marcus Bauser; Bernd Buchmann
Journal:  ChemMedChem       Date:  2016-08-23       Impact factor: 3.466

Review 10.  A Practical Review of Proteasome Pharmacology.

Authors:  Tiffany A Thibaudeau; David M Smith
Journal:  Pharmacol Rev       Date:  2019-04       Impact factor: 25.468

View more
  4 in total

1.  NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells.

Authors:  Shan Li; Feng Wang; Gang Zhang; Tsui-Fen Chou
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

2.  The p97 Inhibitor UPCDC-30245 Blocks Endo-Lysosomal Degradation.

Authors:  Feng Wang; Shan Li; Kai-Wen Cheng; William M Rosencrans; Tsui-Fen Chou
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-07

3.  Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Authors:  Isabelle Rose Leo; Luay Aswad; Matthias Stahl; Elena Kunold; Frederik Post; Tom Erkers; Nona Struyf; Georgios Mermelekas; Rubin Narayan Joshi; Eva Gracia-Villacampa; Päivi Östling; Olli P Kallioniemi; Katja Pokrovskaja Tamm; Ioannis Siavelis; Janne Lehtiö; Mattias Vesterlund; Rozbeh Jafari
Journal:  Nat Commun       Date:  2022-03-30       Impact factor: 14.919

Review 4.  The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1).

Authors:  Michelle A Johnson; Jacob A Klickstein; Richa Khanna; Yunzi Gou; Malavika Raman
Journal:  Neurobiol Dis       Date:  2022-04-08       Impact factor: 7.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.